Why the study?
Does medetomidine reduce dynamic LVOT obstruction in cats with left ventricular hypertrophy?
Does medetomidine reduce dynamic LVOT obstruction in cats with left ventricular hypertrophy?
Medetomidine administration significantly reduces dynamic LVOT obstruction in cats, suggesting it may be a suitable sedative and analgesic agent for this subpopulation.
Hypothesis-generating for medetomidine sedation in cats with dynamic LVOT obstruction; prospective trials needed before clinical adoption.
OBJECTIVE: To evaluate the effects of medetomidine on dynamic left ventricular outflow tract (LVOT) obstruction in cats with left ventricular hypertrophy. DESIGN: Clinical trial. ANIMALS: 6 domestic shorthair cats with echocardiographic evidence of dynamic LVOT obstruction. PROCEDURE: Cats were restrained in lateral recumbency, and baseline M-mode and Doppler echocardiographic examinations were performed. An ECG was recorded continuously, and blood pressure was measured indirectly with Doppler instrumentation. Medetomidine (20 microg/kg 19.1 microg/lb]) was then administered i.m., and examinations were repeated 15 minutes later. RESULTS: Significant decreases in heart rate, LVOT velocity, and the LVOT pressure gradient were documented following medetomidine administration. After adjusting for the effects of heart rate by ANCOVA, there were no significant differences in any other systolic or diastolic indices of left ventricular function. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that administration of medetomidine to cats with dynamic LVOT obstruction may result in elimination of outflow tract obstruction; medetomidine may be a suitable sedative and analgesic agent in this subpopulation of cats.
No takes yet. Share an insight, caveat, or question.
Lamont et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: